Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S, Tan YJ, Baldanti F, Sarasini A, Terres JAR, Nickoloff BJ, Higgs RE, Rocha G, Byers NL, Schlichting DE, Nirula A, Cardoso A, Corbellino M; Sacco Baricitinib Study Group. Stebbing J, et al. Among authors: nickoloff bj. EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24. EMBO Mol Med. 2020. PMID: 32473600 Free PMC article.
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19.
Sims JT, Krishnan V, Chang CY, Engle SM, Casalini G, Rodgers GH, Bivi N, Nickoloff BJ, Konrad RJ, de Bono S, Higgs RE, Benschop RJ, Ottaviani S, Cardoso A, Nirula A, Corbellino M, Stebbing J. Sims JT, et al. Among authors: nickoloff bj. J Allergy Clin Immunol. 2021 Jan;147(1):107-111. doi: 10.1016/j.jaci.2020.08.031. Epub 2020 Sep 10. J Allergy Clin Immunol. 2021. PMID: 32920092 Free PMC article.
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la Peña A, Nunes FP, Janes J, Gamalo M, Donley D, Paik J, DeLozier AM, Nickoloff BJ, Simpson EL. Guttman-Yassky E, et al. Among authors: nickoloff bj. J Am Acad Dermatol. 2019 Apr;80(4):913-921.e9. doi: 10.1016/j.jaad.2018.01.018. Epub 2018 Feb 2. J Am Acad Dermatol. 2019. PMID: 29410014 Clinical Trial.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. Among authors: nickoloff bj. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS. Simpson E, et al. J Am Acad Dermatol. 2020 Sep;83(3):839-846. doi: 10.1016/j.jaad.2020.04.104. Epub 2020 Apr 25. J Am Acad Dermatol. 2020. PMID: 32344071
Loss of miR-204 expression is a key event in melanoma.
Galasso M, Morrison C, Minotti L, Corrà F, Zerbinati C, Agnoletto C, Baldassari F, Fassan M, Bartolazzi A, Vecchione A, Nuovo GJ, Di Leva G, D'Atri S, Alvino E, Previati M, Nickoloff BJ, Croce CM, Volinia S. Galasso M, et al. Among authors: nickoloff bj. Mol Cancer. 2018 Mar 9;17(1):71. doi: 10.1186/s12943-018-0819-8. Mol Cancer. 2018. PMID: 29523154 Free PMC article.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Among authors: nickoloff bj. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Ixekizumab for psoriasis--Authors' reply.
Griffiths CE, Papp KA, Ball SG, Nickoloff BJ. Griffiths CE, et al. Among authors: nickoloff bj. Lancet. 2016 Jan 16;387(10015):226-7. doi: 10.1016/S0140-6736(16)00048-9. Epub 2016 Jan 15. Lancet. 2016. PMID: 26842297 No abstract available.
Treatment of severe lichen planus with cyclosporine.
Ho VC, Gupta AK, Ellis CN, Nickoloff BJ, Voorhees JJ. Ho VC, et al. Among authors: nickoloff bj. J Am Acad Dermatol. 1990 Jan;22(1):64-8. doi: 10.1016/0190-9622(90)70009-7. J Am Acad Dermatol. 1990. PMID: 2298966
383 results